洛美沙星是由Hokurik Seiyaku和Shiono-gi研制的口服喹诺酮抗菌药。其体外抗菌活性与氟嗪酸(Ofloxacin)及氟哌酸(nor-floxacin)相似,但明显大于吡哌酸(Pioemidicacid)。该药与甲氧西林(Methicillin),庆大霉素、氨苄青霉素(ampicillin)及其它抗菌素之间无交叉抗药性。洛美沙星口服后的作用是氟嗪酸的2倍,氟哌酸的2～4倍。该药对治疗尿道,呼吸道及其它感染是高效且安最小抑菌浓度。 Lomefloxacin is an oral quinolone antibacterial agent developed by Hokurik Seiyaku and Shiono-gi. Its in vitro antibacterial activity was similar to Ofloxacin and nor-floxacin, but significantly higher than that of Pioemidic acid. The drug has no cross-resistance with methicillin, gentamicin, ampicillin and other antibiotics. Oral Lomefloxacin role is 2 times the fluorozinc acid, norfloxacin 2 to 4 times. The drug is effective and safe for the treatment of the urethra, respiratory and other infections.